J. Vermeire

Pharmacological Profile of (2R-trans)-4-[1-[3,5-bis(Trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an Orally and Centrally Active Neurokinin-1 Receptor Antagonist

M. Jurzak, J. Leysen, A. Megens, 2002, Journal of Pharmacology and Experimental Therapeutics.

JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.

K. Rhodes, A. Megens, X. Langlois, 2014, ACS chemical neuroscience.

Specific and Fast-Dissociating D 2 Antagonist for the Treatment of Schizophrenia

A. Megens, X. Langlois, G. Macdonald, 2012 .

Pharmacology of JNJ-37822681, a Specific and Fast-Dissociating D2 Antagonist for the Treatment of Schizophrenia

John F. G. Atack, H. Lavreysen, R. Wouters, 2012, Journal of Pharmacology and Experimental Therapeutics.